You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib

Article info

Article menu

This article has a correction. Please see:

XML
Case report
αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib

Authors

  • Juemin Fang Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, ChinaDepartment of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  • Na Ding Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, ChinaCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China PubMed articlesGoogle scholar articles
  • Xianling Guo Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, ChinaDepartment of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  • Yan Sun Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China PubMed articlesGoogle scholar articles
  • Zhiwei Zhang Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, ChinaDepartment of Oncology, Affiliated Hospital of Hebei University of Engineering, Handan 056002, China PubMed articlesGoogle scholar articles
  • Bailu Xie Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China PubMed articlesGoogle scholar articles
  • Zhong Li Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, ChinaShanghai Cell Therapy Research Institute, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China PubMed articlesGoogle scholar articles
  • Hui Wang Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, ChinaDepartment of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  • Wei Mao Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  • Zhicai Lin Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China PubMed articlesGoogle scholar articles
  • Fei Qin Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  • Min Yuan Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, ChinaDepartment of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  • Wenqi Chu Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China PubMed articlesGoogle scholar articles
  • Huanlong Qin Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, ChinaDepartment of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  • Qijun Qian Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, ChinaShanghai Cell Therapy Research Institute, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China PubMed articlesGoogle scholar articles
  • Qing Xu Department of Medical Oncology, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, ChinaDepartment of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Qing Xu; xuqingmd{at}aliyun.com; Dr Qijun Qian; qian{at}shcell.com
View Full Text

Citation

Fang J, Ding N, Guo X, et al
αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib
Journal for ImmunoTherapy of Cancer 2021;9:e001162. doi: 10.1136/jitc-2020-001162

Publication history

  • Accepted November 20, 2020
  • First published February 15, 2021.
Online issue publication 
March 03, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.